#USA #San Antonio #Breast Cancer #Atossa Therapeutics #Z-Endoxifen

Atossa Therapeutics and the Upcoming 2025 San Antonio Breast Cancer Symposium

Atossa Therapeutics, Inc., a prominent player in the biopharmaceutical industry, has announced that four of its research abstracts focusing on (Z)-endoxifen have been accepted for presentation at the highly anticipated 2025 San Antonio Breast Cancer Symposium (SABCS). This symposium will take place from December 9 to 12, 2025, in San Antonio, Texas, and is one of the most critical gatherings for advancing knowledge in the field of breast cancer treatment and prevention.

Dr. Steven Quay, President and CEO of Atossa, expressed enthusiasm about the upcoming presentations, stating, "We are eager to contribute to the scientific community by showcasing our recent findings on (Z)-endoxifen. These studies will highlight the significant advancements we are making in breast cancer treatment and prevention."

Presentation Highlights

The abstracts set for presentation cover a range of important subjects related to breast cancer management. Here are the details of the poster presentations:

1. Initial results from the RECAST DCIS Multicenter platform trial testing active surveillance and novel endocrine therapy agents for DCIS management
Date/Time: Thursday, December 11, 2025, from 12:30 PM to 2:00 PM CT

2. Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
Date/Time: Thursday, December 11, 2025, from 12:30 PM to 2:00 PM CT

3. (Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants via Inactive Conformation Stabilization and Reversal of Mutant ESR1-Associated Transcriptional Signatures
Date/Time: Friday, December 12, 2025, from 7:00 AM to 8:30 AM CT

4. A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs. Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE)
Date/Time: Friday, December 12, 2025, from 12:30 PM to 2:00 PM CT

These presentations will delve into cutting-edge research aimed at addressing significant unmet medical needs within breast cancer therapy, particularly focusing on the efficacy and safety profile of (Z)-endoxifen. This compound is a novel therapeutic agent that has shown promise in recent studies, particularly in its ability to target estrogen receptor pathways critical to the growth and survival of certain breast cancer cells.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is committed to innovating and advancing therapies that address substantial gaps in breast cancer treatment. The company’s research strategy revolves around efficient capital allocation, emphasizing rigorous program development and data accumulation to meet regulatory standards and facilitate potential commercialization. For further details, you can visit their website at Atossa Therapeutics.

Looking Ahead

As Atossa prepares for its presentations at the SABCS, the biopharmaceutical community is keenly interested in the outcomes of these studies. The research around (Z)-endoxifen may prove to be a pivotal step in the fight against breast cancer, and further insights from these presentations are eagerly awaited by both medical professionals and patients alike. As we approach the symposium, the data shared by Atossa will undoubtedly contribute significantly to ongoing discussions regarding innovative treatment approaches in oncology.

In conclusion, Atossa’s participation in the 2025 SABCS not only highlights their ongoing commitment to breast cancer research but also underscores the importance of continued exploration in the field to improve patient outcomes. With the ongoing advancements in treatment protocols, Atossa's efforts may very well lead to transformative changes in how breast cancer is managed today.